Physician profile
Amit Bharara
NPI 1255567962
$100,490.15
in general payments reported to CMS, 2019-2025
18 companies · $98K in 2025
The $98K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $39.50 · 2021: $214 · 2022: $521 · 2023: $518 · 2024: $842 · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Travel and Lodging: $4,000 · Food and Beverage: $3,094 · Consulting Fee: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,882.00 |
| Travel and Lodging | $4,000.46 |
| Food and Beverage | $3,094.11 |
| Consulting Fee | $1,581.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $98,014.99 | 2022-2025 | |
| Glaxosmithkline, LLC. | $833.85 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $450.17 | 2020-2025 | Fasenra, Tezspire, Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.70 | 2021-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $167.91 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $131.10 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.68 | 2021-2024 | Glassia |
| Electromed, INC. | $78.35 | 2022-2023 | Smartvest |
| Sunovion Pharmaceuticals INC. | $76.37 | 2019 | |
| Mylan Specialty L.P. | $55.39 | 2023-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $46.00 | 2023-2024 | Acthar |
| Philips North America LLC | $45.67 | 2023-2024 | (Ak6) Vest Therapy |
| Harmony Biosciences LLC | $42.76 | 2021-2023 | Wakix |
| Genentech USA, INC. | $41.25 | 2019-2023 | Xolair |
| Baxter Healthcare | $34.63 | 2024 | Hillrom - Vest System Model 105 Home Care |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $21.29 | 2022 | |
| United Therapeutics Corporation | $18.84 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Bharara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.